CN1050127C - 苯并环庚烯和苯并氧杂䓬其制备方法和含有它们的药物组合物 - Google Patents

苯并环庚烯和苯并氧杂䓬其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN1050127C
CN1050127C CN93120135A CN93120135A CN1050127C CN 1050127 C CN1050127 C CN 1050127C CN 93120135 A CN93120135 A CN 93120135A CN 93120135 A CN93120135 A CN 93120135A CN 1050127 C CN1050127 C CN 1050127C
Authority
CN
China
Prior art keywords
pyridyl
dimethyl
group
dihydro
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93120135A
Other languages
English (en)
Chinese (zh)
Other versions
CN1097752A (zh
Inventor
J·J·博瑟朗
M·布鲁耐特
M·诺布莱特
P·杜尔宾
D·古尔里尔
T·N·鲁昂格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN1097752A publication Critical patent/CN1097752A/zh
Application granted granted Critical
Publication of CN1050127C publication Critical patent/CN1050127C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN93120135A 1992-12-07 1993-12-06 苯并环庚烯和苯并氧杂䓬其制备方法和含有它们的药物组合物 Expired - Fee Related CN1050127C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FRP.V.9214720 1992-12-07
FR9214720A FR2698873B1 (fr) 1992-12-07 1992-12-07 Benzocycloheptènes, benzoxépines et benzothiépines activateurs des canaux potassiques, procédé de préparation, composition pharmaceutique les contenant.

Publications (2)

Publication Number Publication Date
CN1097752A CN1097752A (zh) 1995-01-25
CN1050127C true CN1050127C (zh) 2000-03-08

Family

ID=9436308

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120135A Expired - Fee Related CN1050127C (zh) 1992-12-07 1993-12-06 苯并环庚烯和苯并氧杂䓬其制备方法和含有它们的药物组合物

Country Status (29)

Country Link
US (2) US5602152A (enExample)
EP (1) EP0626954B1 (enExample)
JP (1) JPH07503977A (enExample)
KR (1) KR100236810B1 (enExample)
CN (1) CN1050127C (enExample)
AT (1) ATE177742T1 (enExample)
AU (1) AU680856B2 (enExample)
CA (1) CA2129642A1 (enExample)
CZ (1) CZ184894A3 (enExample)
DE (1) DE69324001T2 (enExample)
DK (1) DK0626954T3 (enExample)
ES (1) ES2132373T3 (enExample)
FI (1) FI943646L (enExample)
FR (1) FR2698873B1 (enExample)
GR (1) GR3030514T3 (enExample)
HU (1) HUT67852A (enExample)
IL (1) IL107891A0 (enExample)
LT (1) LT3167B (enExample)
LV (1) LV10451B (enExample)
NO (1) NO942914L (enExample)
NZ (1) NZ258896A (enExample)
PL (1) PL174246B1 (enExample)
RO (1) RO113040B1 (enExample)
RU (1) RU2127268C1 (enExample)
SI (1) SI9300632A (enExample)
SK (1) SK93994A3 (enExample)
TW (1) TW276255B (enExample)
WO (1) WO1994013658A2 (enExample)
ZA (1) ZA939127B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
CN1084741C (zh) * 1994-09-13 2002-05-15 孟山都公司 具有回肠胆汁酸转运和牛磺胆酸盐摄入抑制剂作用的新的苯并硫杂䓬
US5952326A (en) * 1997-12-10 1999-09-14 Pfizer Inc. Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases
KR20010034114A (ko) * 1998-01-14 2001-04-25 니뽄 신야쿠 가부시키가이샤 칼륨 채널 활성화제
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
WO2000038726A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
EP1140190B1 (en) 1998-12-23 2002-11-20 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and bile acid sequestering agents for cardiovascular indications
PT1140187E (pt) * 1998-12-23 2004-01-30 Searle Llc Combinacoes de um inibidor de ibat e de um inibidor de mtp para indicacoes cardiovasculares
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
IL143949A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
ATE240120T1 (de) * 1998-12-23 2003-05-15 Searle Llc Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
HK1052183A1 (zh) 2000-03-10 2003-09-05 Pharmacia Corporation 制造tetrahydrobenzothiepines的方法
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー.ディー. サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送(asbt)およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
RU2387648C1 (ru) * 2008-12-15 2010-04-27 Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" Способ получения алкиловых эфиров 3-оксо-1,3-дигидробензо[с]оксепин-4-карбоновой кислоты
US20140323412A1 (en) 2011-10-28 2014-10-30 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
SG10201909122QA (en) 2011-10-28 2019-11-28 Lumena Pharmaceuticals Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
EP2834216A1 (en) 2012-04-04 2015-02-11 Catylix Inc. Selective androgen receptor modulators
KR102909548B1 (ko) * 2024-06-24 2026-01-07 정종기 변압기 압력조절장치

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107972A (ja) * 1986-06-20 1988-05-12 Suntory Ltd 2−フェニルベンズオキセピン誘導体及び該誘導体を含有する医薬
EP0360131A1 (de) * 1988-09-17 1990-03-28 Hoechst Aktiengesellschaft 2,3,4,5-Tetrahydro-1-benzoxepine, Verfahren zu ihrer Herstellung, ihre Verwendung sowie pharmazeutische Präparate auf Basis dieser Verbindungen
US5112839A (en) * 1989-07-07 1992-05-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1593760A1 (de) * 1967-02-01 1972-06-08 Boehringer Sohn Ingelheim Verfahren zur Herstellung neuer Benz-epinderivate
US3444176A (en) * 1967-04-28 1969-05-13 Mcneilab Inc Certain 4-diloweralkylamino-lower alkyl - 5 - pyridyl (or phenyl)-2,3-dihydro - 1 - benzothiepins and derivatives thereof
AU8402275A (en) * 1974-08-26 1977-02-17 Takeda Chemical Industries Ltd Benzocycloheptene derivatives
US4066663A (en) * 1976-07-01 1978-01-03 Syntex (U.S.A.) Inc. 6,11-Dihydrodibenzo-[b. e.]-thiepin-11-one-3-aldehyde and 3-acetal derivatives
ATE23718T1 (de) 1981-09-25 1986-12-15 Beecham Group Plc Benzopyran-verbindungen mit pharmazeutischer wirkung.
US4416687A (en) * 1982-02-01 1983-11-22 Monsanto Company 3,5-Bis (trifluoromethyl)phenoxy carboxylic acids and derivatives thereof
PH22343A (en) * 1983-02-15 1988-08-12 Merrell Dow Pharma 2h-(1) benzoxepino (5,4-b) 1,4-oxazine derivatives
NZ219311A (en) * 1986-02-27 1989-04-26 Janssen Pharmaceutica Nv Imidazoles and herbicidal compositions
DE3726261A1 (de) 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
US4971982A (en) * 1987-07-06 1990-11-20 Hoffmann-La Roche Inc. Benzopyran derivatives
GB8812765D0 (en) * 1988-05-28 1988-06-29 Beecham Group Plc Novel compounds
JP3018386B2 (ja) * 1990-01-24 2000-03-13 吉富製薬株式会社 光学活性なベンゾチエピノピリダジン化合物の製造法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63107972A (ja) * 1986-06-20 1988-05-12 Suntory Ltd 2−フェニルベンズオキセピン誘導体及び該誘導体を含有する医薬
EP0360131A1 (de) * 1988-09-17 1990-03-28 Hoechst Aktiengesellschaft 2,3,4,5-Tetrahydro-1-benzoxepine, Verfahren zu ihrer Herstellung, ihre Verwendung sowie pharmazeutische Präparate auf Basis dieser Verbindungen
US5112839A (en) * 1989-07-07 1992-05-12 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives

Also Published As

Publication number Publication date
FR2698873A1 (fr) 1994-06-10
AU5697594A (en) 1994-07-04
US5652252A (en) 1997-07-29
KR950700278A (ko) 1995-01-16
NO942914L (no) 1994-08-05
TW276255B (enExample) 1996-05-21
RU94040853A (ru) 1996-07-10
LT3167B (en) 1995-02-27
DK0626954T3 (da) 1999-10-11
KR100236810B1 (ko) 2000-02-01
CZ184894A3 (en) 1995-02-15
AU680856B2 (en) 1997-08-14
DE69324001D1 (de) 1999-04-22
IL107891A0 (en) 1994-04-12
US5602152A (en) 1997-02-11
FR2698873B1 (fr) 1995-02-24
ES2132373T3 (es) 1999-08-16
EP0626954B1 (en) 1999-03-17
NO942914D0 (enExample) 1994-08-05
PL304719A1 (en) 1995-01-09
ZA939127B (en) 1994-08-05
LV10451B (en) 1995-12-20
DE69324001T2 (de) 1999-10-07
FI943646A7 (fi) 1994-08-05
FI943646A0 (fi) 1994-08-05
GR3030514T3 (en) 1999-10-29
SK93994A3 (en) 1995-04-12
JPH07503977A (ja) 1995-04-27
WO1994013658A2 (en) 1994-06-23
HUT67852A (en) 1995-05-29
ATE177742T1 (de) 1999-04-15
SI9300632A (en) 1994-09-30
CA2129642A1 (en) 1994-06-23
HU9402302D0 (en) 1994-10-28
RU2127268C1 (ru) 1999-03-10
FI943646L (fi) 1994-08-05
PL174246B1 (pl) 1998-07-31
EP0626954A1 (en) 1994-12-07
RO113040B1 (ro) 1998-03-30
LV10451A (lv) 1995-02-20
LTIP1525A (en) 1994-07-15
CN1097752A (zh) 1995-01-25
NZ258896A (en) 1996-03-26
WO1994013658A3 (en) 1994-08-04

Similar Documents

Publication Publication Date Title
CN1050127C (zh) 苯并环庚烯和苯并氧杂䓬其制备方法和含有它们的药物组合物
CN1090184C (zh) 杂环化合物及其制备方法
CN1031570C (zh) 吡唑并吡啶化合物的制备方法
CN1036920C (zh) 含杂环碳酸衍生物
CN1032203C (zh) 制备取代2-吡啶酮和吡啶-2-硫酮的方法
CN1211362C (zh) 新的苯并噻吩、苯并呋喃和吲哚化合物,它们的制备方法及含有它们的药物组合物
CN1073174A (zh) 杂环衍生物
CN1173132A (zh) 二氢嘧啶类化合物及其用途
HK1045311B (zh) 与多巴胺d3受体具有亲和力的三唑化合物
CN85108623A (zh) 制备具有药用活性的杂环酰胺之新方法
CN1021823C (zh) 治疗哮喘、关节炎等疾病用的取代的苯并二氢吡喃化合物的制品方法
CN1238761A (zh) 苯甲酰胺醛及其作为半胱氨酸蛋白酶抑制剂的用途
CN1234025A (zh) 1-苯基-苯并咪唑类化合物及其作为baga-a受体调节剂的用途
CN1268133A (zh) 含有稠合环取代基的作为nos抑制剂的2-氨基吡啶
CN1053658C (zh) 氨基芪唑衍生物和药
CN88101588A (zh) 制备1,4-二取代的哌嗪类化合物的方法
CN1202894A (zh) 用于治疗变态反应疾病的取代的4-(1 h-苯并咪唑-2-基-氨基)哌啶
CN1286683A (zh) 四氢苯并吲哚衍生物
CN1013442B (zh) 新双环化合物的制备方法
CN1064864A (zh) 取代的四氢化萘及有关化合物的制备方法
CN1033991A (zh) 取代羟胺类
CN1049161A (zh) 具有血清素2-受体拮抗活性的杂环化合物
CN1057839A (zh) 用于治疗哮喘、关节炎及相关疾病的氮杂苯并咪唑
CN1240443A (zh) 新的羧基取代的环状羧酰胺衍生物
CN1029403C (zh) 新的2-氧代-1-氧杂-8-氮杂螺[4,5]癸烷衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee